Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents
HM Zhou, JG Zhang, X Zhang, Q Li - Signal transduction and targeted …, 2021 - nature.com
Cancer stem cells (CSCs) show a self-renewal capacity and differentiation potential that
contribute to tumor progression and therapy resistance. However, the underlying processes …
contribute to tumor progression and therapy resistance. However, the underlying processes …
Soft‐tissue sarcoma in adults: an update on the current state of histiotype‐specific management in an era of personalized medicine
AC Gamboa, A Gronchi… - CA: a cancer journal for …, 2020 - Wiley Online Library
Soft‐tissue sarcomas (STS) are rare tumors that account for 1% of all adult malignancies,
with over 100 different histologic subtypes occurring predominately in the trunk, extremity …
with over 100 different histologic subtypes occurring predominately in the trunk, extremity …
Nirogacestat, a γ-secretase inhibitor for desmoid tumors
Background Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors
without approved treatments. Methods We conducted a phase 3, international, double-blind …
without approved treatments. Methods We conducted a phase 3, international, double-blind …
[HTML][HTML] Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Highlights•This Clinical Practice Guideline provides key recommendations on the
management of soft tissue and visceral sarcomas.•Recommendations have been agreed …
management of soft tissue and visceral sarcomas.•Recommendations have been agreed …
[HTML][HTML] The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients
B Alman, S Attia, C Baumgarten, C Benson… - European Journal of …, 2020 - Elsevier
Desmoid tumor (DT; other synonymously used terms: Desmoid-type fibromatosis,
aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic …
aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic …
Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy
The Kirsten rat sarcoma (KRAS) oncoprotein has been on drug hunters list for decades now.
Initially considered undruggable, recent advances have successfully broken the **x through …
Initially considered undruggable, recent advances have successfully broken the **x through …
NCCN guidelines insights: soft tissue sarcoma, version 1.2021: featured updates to the NCCN guidelines
M von Mehren, JM Kane, MM Bui, E Choy… - Journal of the National …, 2020 - jnccn.org
The NCCN Guidelines for Soft Tissue Sarcoma provide recommendations for the diagnosis,
evaluation, treatment, and follow-up for patients with soft tissue sarcomas. These NCCN …
evaluation, treatment, and follow-up for patients with soft tissue sarcomas. These NCCN …
Current management of desmoid tumors: a review
Importance Desmoid tumor (DT) is a rare and locally aggressive monoclonal, fibroblastic
proliferation characterized by a variable and often unpredictable clinical course. Previously …
proliferation characterized by a variable and often unpredictable clinical course. Previously …
UK guidelines for the management of soft tissue sarcomas
Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues and can occur
almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location …
almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location …
Desmoid tumors: a comprehensive review
M Bektas, T Bell, S Khan, B Tumminello… - Advances in …, 2023 - Springer
Desmoid tumors (DT) are rare, locally aggressive, fibroblastic soft-tissue tumors that are
characterized by infiltrative growth and can affect organs and adjacent structures, resulting …
characterized by infiltrative growth and can affect organs and adjacent structures, resulting …